Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the Akt inhibitor MK2206 in patients with progressive, recurrent, or metastatic adenoid cystic carcinoma of the salivary gland…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma of the Oral Cavity
• Adenoid Cystic Carcinoma of the Salivary Gland
• Salivary Gland Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-06-26